A simple blood test could speed up diagnosis and improve outcomes for children with Africa's most common childhood cancer.

Two international studies, a clinical trial led by the University of Oxford and University of Utrecht, and a qualitative study led by the University of Oxford and University of Antwerp, report that point-of-care diagnostic testing, when used alone is unlikely to reduce antibiotic prescribing for respiratory tract infections in primary care. The findings indicate that testing must be embedded within broader antimicrobial stewardship strategies to be effective.

The University of Oxford and Serum Institute of India Pvt. Ltd. (SII), a Cyrus Poonawalla Group company and the world's largest vaccine manufacturer, have signed an Intellectual Property license agreement to advance the development and manufacture of the ChAdOx1 NipahB vaccine candidate.

The University of Oxford's Social Sciences Division will host the Social Sciences Impact Conference on 24-25 March 2026 at St Anne's College, Oxford - bringing together researchers, policymakers, practitioners and innovators to explore how social science can help address complex challenges and deliver meaningful change. The 2026 conference theme, Impact in Motion: Navigating Uncertainty, Creating Change , will examine how collaboration, openness, innovation and inclusion can help societies respond constructively in a rapidly changing world.

The Stephen A. Schwarzman Centre , a new world-class centre for the Arts and Humanities in Oxford, will launch its public programme on 25 April 2026 with a day of free events and performances. The new academic and cultural centre provides a unique mix of exceptional performance and research spaces alongside academic teaching facilities. 

Researchers at the University of Oxford have developed a "Stroke Cognition Calculator", a new tool designed to estimate a person's chance of having thinking and memory problems six months after a stroke.

Dr Stuart Jenkins , Oxford Net Zero Research Fellow on Net Zero for the Fossil Fuel Sector, assesses whether new North Sea oil and gas strengthens the UK's energy security and economy.

Oxford University spinout Dark Blue Therapeutics has been acquired by global biotechnology company Amgen in a deal worth up to US$840 million, marking a major milestone for Oxford-led cancer research and innovation. The deal reflects years of collaborative, multidisciplinary work across the University and its partners to translate fundamental research into promising new medicines.

Research published in Science Advances has uncovered new insights into why the most aggressive oesophageal cancers are so difficult to treat and how the body's own defence systems are helping them to thrive.

The World Health Organization (WHO) has designated the Nuffield Department of Primary Care Health Sciences at the University of Oxford as the WHO Collaborating Centre on Primary Health Care.

Two companion studies, published in Cell Genomics , reveal how brain development lays the foundation for both shared and sex-specific circuits, redefining how neural diversity arises. A preview article l'inked to the report highlights the broader significance of these findings and places them in context for the field.

An AI-driven tool that tailors antidepressant treatment to individual patients was shown to improve outcomes for people with depression, compared to standard treatment, in a major international trial.

A new analysis of Child Measurement Programme data from England, Scotland, and Wales challenges recent reports suggesting children in Britain are getting shorter. The analysis, conducted by researchers at the University of Oxford, reveals that average child height has increased over the past two decades. But these gains are not related to improved child health, the researchers say. The increases in average height are closely linked to rising childhood obesity among poorer children and widening socioeconomic inequalities.

A new multinational study from the INTERCOVID Consortium, led by researchers from the University of Oxford, has found that COVID-19 vaccination during pregnancy, particularly when combined with a booster dose, significantly reduces the risk of preeclampsia, a serious and potentially life-threatening pregnancy complication. The findings offer unprecedented insight into preeclampsia prevention, independent of the direct effects of COVID-19 infection.